Andras Strassz
Chief Medical Officer Heidelberg Pharma
Seminars
Wednesday 5th November 2025
Contextualizing Learnings From Phase I Clinical Design & Development of HDP-101
2:00 pm
- Detailing phase I clinical data of HDP-101 targeting BCMA in multiple myeloma
- Focusing on critical study design elements and challenges when developing a novel payload
- Presenting study flow focusing on challenges and adaptations on clinical trial design and development strategy
- Benefitting from adaptive clinical trial design by allowing flexibility in ADC dose escalation
